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mary, our data demonstrate antiproliferative and apoptotic 
effects of RAD001 in NET cells in vitro supporting its clinical 
use in current phase II trials in NET patients. 
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 Introduction 
 The phosphatidylinositol-3-kinase (PI(3)K)/Akt/
mTOR pathway is crucial for the regulation of cell sur-
vival and proliferation. Growth factors of the insulin 
family, including insulin, insulin-like growth factor I 
(IGF-I) and IGF-II, initiate PI(3)K/Akt/mTOR signaling 
by activating insulin/IGF-I receptor tyrosine kinases 
(RTKs), which in turn leads to tyrosine phosphoryla-
tion of insulin receptor substrate (IRS) proteins and
subsequent recruitment of PI(3)K. PI(3)K bound to
IRS converts phosphatidylinositol-4,5-bisphosphate 
(PtdIns(4,5)P 2 ) into the lipid second-messenger phos-
phatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P 3 ), 
an event that is negatively regulated by phosphatase and 
tensin homologue deleted on chromosome 10 (PTEN). 
PtdIns(3,4,5)P 3  eventually recruits Akt to the plasma 
membrane thereby facilitating its activation by phospha-
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 Abstract 
 Background/Aim: Tumors exhibiting constitutively activat-
ed PI(3)K/Akt/mTOR signaling are hypersensitive to mTOR 
inhibitors such as RAD001 (everolimus) which is presently 
being investigated in clinical phase II trials in various tumor 
entities, including neuroendocrine tumors (NETs). However, 
no preclinical data about the effects of RAD001 on NET cells 
have been published. In this study, we aimed to evaluate the 
effects of RAD001 on BON cells, a human pancreatic NET cell 
line that exhibits constitutively activated PI(3)K/Akt/mTOR 
signaling.  Methods: BON cells were treated with different 
concentrations of RAD001 to analyze its effect on cell growth 
using proliferation assays. Apoptosis was examined by West-
ern blot analysis of caspase-3/PARP cleavage and by FACS 
analysis of DNA fragmentation.  Results: RAD001 potently in-
hibited BON cell growth in a dose-dependent manner which 
was dependent on the serum concentration in the medium. 
RAD001-induced growth inhibition involved G0/G1-phase 
arrest as well as induction of apoptosis.  Conclusion: In sum-
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tidylinositol-3-dependent kinase1 (PDK1). Activated Akt 
promotes resistance to apoptosis and unrestricted cell 
growth through coordinated phosphorylation of multi-
ple downstream targets. One major effector of Akt signal-
ing is the serine/threonine protein kinase mammalian 
target of rapamycin (mTOR). Complexed with regulato-
ry-associated protein of mTOR (raptor) and LST8 in 
mTORC1, mTOR acts as a key integrator of signals from 
growth factors and nutrients (e.g. amino acids and glu-
cose)  [1, 2] . Two well-characterized mTOR substrates are 
eukaryotic translation initiation factor 4E (eIF4E)-bind-
ing protein (4EBP1) and p70 ribosomal S6 kinase 
(p70S6K), both regulating transcription and translation 
initiation of critical growth genes. Activated p70S6K also 
mediates phosphorylation and subsequent proteasome-
mediated degradation of IRS-1, the major substrate of the 
IGF-I/insulin receptors. Thus, p70S6K forms part of a 
powerful negative feedback mechanism of PI(3)K/Akt/
mTOR signaling  [3] .
 Activating mutations in one or another PI(3)K/Akt/
mTOR pathway component, e.g. PTEN, occur in a wide 
range of tumors, contributing to resistance to apoptosis 
and unrestricted cell growth. Significantly, tumors har-
boring such mutations are hypersensitive to mTOR in-
hibitors  [4, 5] . The rapamycin-derivative RAD001 (40-
O-(2-hydroxyethyl)-rapamycin, Novartis Pharma) is a 
potent, orally bioavailable mTOR inhibitor. RAD001 in-
duces growth inhibition in a variety of tumor cell lines 
in vitro and a range of animal models of cancer  [6–9] . 
Moreover, RAD001 has been shown to sensitize tumor 
cells to conventional therapeutic antitumor agents and 
radiation  [7, 10–12] . RAD001 is presently being investi-
gated in clinical phase II trials in various tumor entities, 
including NETs.
 NETs represent a rare and heterogeneous category of 
tumors. The majority of NETs show already local or dis-
tant metastasis at the time of diagnosis  [13, 14] . Advanced 
stages are characterized mainly by hepatic metastases 
with a 5-year survival rate of less than 50%  [14–16] . Cur-
rently available antiproliferative strategies against NETs 
of the GEP are only of moderate efficacy. While well-dif-
ferentiated NETs of pancreatic origin demonstrate mod-
est sensitivity to conventional chemotherapy regimens, 
no established chemotherapy protocol exists for NETs of 
midgut origin  [15, 17–19] . Since lost expression of the 
PI(3)K antagonist PTEN occurs in 54% of poorly differ-
entiated neuroendocrine carcinomas and 76% of all NETs 
display constitutive Akt phosphorylation  [20, 21] , a ma-
jority of NETs is likely to be accessible to targeted anti-
proliferative therapy with mTOR inhibitors. Here, we 
evaluate the in vitro effects of RAD001 on BON cells. 
This cell line, derived from a human pancreatic neuroen-
docrine tumor, exhibits constitutive Akt/mTOR phos-
phorylation due to an autocrine IGF-I loop  [22–24] . We 
demonstrate that RAD001 induces potent antiprolifera-
tive effects due to G0/G1 cell cycle arrest and apoptosis. 
In summary, our data indicate the novel mTOR inhibitor 
RAD001 to be a promising agent for targeted antiprolif-
erative NET therapy.
 Materials and Methods 
 Reagents 
 DMEM/F12 (1:  1) medium and penicillin/streptomycin were 
from Gibco/Invitrogen (Karlsruhe, Germany). Amphotericin B 
and fetal calf serum (FCS) were purchased from Biochrom (Ber-
lin, Germany). RAD001 was kindly provided by Novartis Phar-
ma (Basel, Switzerland). Antibodies against pp70S6 Kinase 
(#9234), p70S6 Kinase (#9202), pAkt (#9271), Akt (#9272), 
pGSK3 (#9331), GSK3 (#9315), cyclin D1 (#2926), p27Kip1 
(#2552), caspase-3 (#9662) and PARP (#9542) were from Cell Sig-
naling (Beverly, Mass., USA). Antibody against   -actin (#A5441) 
was from Sigma-Aldrich (St. Louis, Mo., USA). Horseradish per-
oxidase-conjugated secondary antibodies to mouse (#31432) or 
rabbit (#31452) IgG and chemiluminescent substrate SuperSignal 
West Dura Extended Duration Substrate were from Pierce (Rock-
ford, Ill., USA). 
 Cell Culture 
 Human pancreatic neuroendocrine BON tumor cells were 
kindly provided by R. Göke (Marburg, Germany). BON cells were 
cultured in DMEM/F12 (1:  1) medium supplemented with 10% 
FCS, 1% penicillin/streptomycin and 0.4% amphotericin B in a 
5% CO 2  atmosphere. 
 Cell Proliferation Assay 
 For proliferation assays, BON cells were seeded into 96-well 
plates at a density of 2000 cells/well and grown for 24 h. The next 
day, medium was replaced by serum-rich medium (10% FCS) or 
serum-depleted medium (1% FCS) containing various concentra-
tions of RAD001 (25, 30, 35, 40, 45, 50, 55 n M or 5, 10, 15, 20, 25, 
30, 35 n M ) for 72 h. The cell proliferation rate was measured with 
Cell Titer 96 kit (Promega, Madison, Wisc., USA) according to the 
manufacturer’s instructions. Following 3 h of incubation with 
Cell Titer 96 solution, absorbance at 492 nm was determined us-
ing an ELISA plate reader.
 Measurement of Apoptosis and Cell Cycle Analysis 
 Apoptosis and cell cycle distribution were analyzed using flow 
cytometry according to Nicoletti et al.  [25] . Cells were scraped 
with a rubber policeman, washed with PBS and incubated in 
staining buffer containing 0.1% sodium citrate, 0.1% Triton X-100 
(Sigma) and 50   g/ml propidium iodide overnight. Sub-G1 events 
and cell cycle distribution were measured in a fluorescence-acti-
vated cell sorter, FACSCalibur (Becton Dickinson, Franklin 
Lakes, N.J., USA), using Cell Quest  software. Nuclei to the left 
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of the ‘G1-peak’ containing hypodiploid DNA were considered 
apoptotic.
 Protein Extraction and Western Blotting 
 Protein extraction and Western blotting were performed as 
described recently  [26, 27] . Briefly, cells were lysed in 500   l
lysis buffer. The lysates were centrifuged for 10 min at 4  °  C and 
13,000  g and supernatants were diluted 1:  1 with SDS sample buf-
fer. Samples were boiled for 5 min and separated on a SDS poly-
acrylamide gel. Proteins were electrotransferred for 60 min onto 
PVDF membranes (Immobilone; Millipore, Eschborn, Germa-
ny) using a semi-dry Western-blot technique. After blocking in 
2% non-fat dried milk, the membranes were incubated over-
night in appropriate dilutions of antibodies against pp70S6K
(1:  2,000), pAkt (1:  5,000), pGSK3 (1:  5,000), cyclin D1 (1:  2,000), 
p27Kip1 (1:  1,000), caspase-3 (1:  1,000) and PARP (1:  20,000). Af-
ter washing with PBS, the membranes were incubated with per-
oxidase-conjugated secondary antibody (1:  25,000) for 2 h. The 
blots were washed and immersed in the chemiluminescent sub-
strate for 30 min and exposed to XOMAT-AR film (Eastman 
Kodak, Rochester, N.Y., USA). Afterwards, the membranes were 
stripped and incubations with antibodies against p70S6K
(1:  1,000), Akt (1:  5,000) and GSK3 (1:  5,000) were performed as 
described above.
 Statistical Analysis 
 National Institutes of Health Image 1.59 software was used for 
densitometric analysis of specific bands in Western blots. Statisti-
cal analysis was performed using a two-tailed Student’s t test. p  ! 
0.05 was considered statistically significant.
 Results 
 RAD001 Inhibits Proliferation 
 To investigate the effects of RAD001 on the prolif-
eration of neuroendocrine BON tumor cells, we per-
formed proliferation assays. A 72-hour exposure to 
RAD001 inhibited BON cell proliferation in a dose-de-
pendent manner, which was strongly dependent on se-
rum concentration. When RAD001 was added to the 
cells in serum-rich medium (10% FCS), a concentration 
of 35 n M reduced cell proliferation by   50% ( fig. 1 a). 
An equal reduction of cell proliferation was achieved 
with only 20 n M RAD001, when cells were cultured in 
serum-depleted medium (1% FCS;  fig. 1 b). For further 
experiments serum-depleted medium (1% FCS) was 
used.
 RAD001 Inhibits Phosphorylation of p70S6K 
 BON cells have been shown to serum-independently 
exhibit constitutive phosphorylation of p70S6K due to an 
autocrine IGF-I loop  [24] . In preliminary experiments, 
we also found p70S6K to be constitutively activated in 
BON cells, even after cul tivation in serum-free medium 
for 5 days (data not shown). Treatment of BON cells with 
the mTOR inhibitor RAD001 (20 n M ) potently inhibited 
p70S6K phosphorylation ( fig. 2 a).
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 Fig. 1. RAD001 inhibits proliferation. BON cells were incubated with indicated concentrations of RAD001 in 
( a ) serum-rich medium (10% FCS) or ( b ) serum-depleted medium (1% FCS) for 72 h. The cell proliferation rate 
was measured with Cell Titer 96 kit (Promega). Values are demonstrated as average and SD of 3 independently 
performed experiments. p  ! 0.001 vs. untreated control for all concentrations. 
 Antiproliferative Effects of RAD001 on 
Neuroendocrine Tumor Cells 
Neuroendocrinology 2007;85:54–60 57
 RAD001 Increases Phosphorylation of Akt and Its 
Downstream Target GSK-3  /  
 Rapamycin has recently been observed to upregulate 
the level of phosphorylated Akt in several human cancer 
cell lines  [3, 28] . Consistently, mTOR inhibition by 
RAD001 significantly increased phosphorylation of Akt 
and its downstream target GSK-3  /  ( fig. 2 b).
 RAD001 Induces G0/G1 Cell Cycle Arrest 
 The antiproliferative activity of mTOR inhibitors is as-
sumed to be primarily due to G0/G1-phase arrest  [6] . In 
BON cells, only high concentrations of RAD001 ( 6 25 
n M ) induced G0/G1-phase arrest, thereby significantly 
decreasing the fraction of BON cells in the S-phase 
( fig. 3 a). Western blot analysis revealed RAD001 to dose-
dependently decrease the protein level of cyclin D1, while 
only high concentrations of RAD001 ( 6 25 n M ) strongly 
induced p27Kip1 protein expression ( fig. 3 b)
 RAD001 Induces Apoptosis 
 In a relatively limited number of studies, rapamycin 
induced apoptosis, which seemed to be dose-independent 
 [6] . To assess this issue, the extent of RAD001-induced 
apoptosis was studied by Western blot analysis of cas-
pase-3/PARP cleavage and DNA fragmentation. A 24-
hour exposure of BON cells to RAD001 dose-depend-
ently decreased the amount of uncleaved caspase-3 and 
simultaneously increased the fraction of cleaved PARP 
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 Fig. 2.  a RAD001 inhibits phosphorylation of p70S6K. BON cells 
were treated with 20 n M RAD001 for indicated times. Protein ex-
pression level of phosphorylated and total p70S6K was examined 
using Western blot analysis. One representative blot out of 3 per-
formed experiments is shown.  b RAD001 increases phosphoryla-
tion of Akt and its downstream target GSK-3  /  . BON cells were 
treated with 20 n M RAD001 for indicated times. Protein expres-
sion levels of phosphorylated and total Akt and GSK-3  /  were 
examined using Western blot analysis. For each protein, one rep-
resentative blot out of 3 performed experiments is shown. 
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 Fig. 3.  a RAD001 induces G0/G1 cell cycle arrest. BON cells were 
incubated with indicated concentrations of RAD001 for 48 h. 
Subsequently, the proportion of cells in G0/G1-, S- and G2/M-
phase was analyzed by flow cytometry. Values are demonstrated 
as average and SD of triplicate values from the same experiment 
and were confirmed by 3 independent separate experiments.
 * p  ! 0.05 for G0/G1-phase fraction vs. untreated control;  +++  p  ! 
0.001 for S-phase fraction vs. untreated control.  b RAD001 de-
creases the protein level of cyclin D1 and induces p27Kip1 protein 
expression. BON cells were incubated with indicated concentra-
tions of RAD001 for 24 h. Protein expression levels of cyclin D1 
and p27Kip1 were examined using Western blot analysis. Equal 
loading was confirmed by detection of   -actin. For both proteins, 
one representative blot out of 3 performed experiments is 
shown. 
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( fig. 4 a). In addition, treatment with RAD001 dose-de-
pendently increased the number of sub-G1 events 
( fig. 4 b). 
 Discussion 
 Constitutive activation of the PI(3)K/Akt/mTOR path-
way seems to be a common mechanism, by which tumor 
cells promote cell growth and survival. Recent studies 
revealed activating mutations in the PI(3)K/Akt/mTOR 
pathway to occur in about one third to one half of all hu-
man tumors  [1, 29, 30] . In such tumors, mTOR inhibition 
seems to be a promising strategy for overcoming resis-
tance to apoptosis and unrestricted cell growth  [4, 5] . 
Since 54% of poorly differentiated neuroendocrine carci-
nomas lack expression of the PI3K antagonist PTEN and 
76% of all NETs display constitutive Akt phosphoryla-
tion, a majority of NETs is likely to be accessible to tar-
geted antiproliferative therapy with mTOR inhibitors 
 [20, 21] . BON cells exhibit constitutively activated PI(3)K/
Akt/mTOR signaling due to an autocrine IGF-I loop and 
have been previously shown to be sensitive to rapamycin-
mediated antiproliferative effects  [24] . Here we demon-
strate the novel rapamycin derivative RAD001 to potent-
ly induce growth inhibition in the human pancreatic 
neuroendocrine BON tumor cells in vitro. We found the 
growth inhibitory efficacy of RAD001 to be attenuated in 
serum-rich medium and suggest this to be due to (1) 
growth factors in the serum that stimulate alternative 
survival pathways thus partially rescuing cells from 
RAD001-mediated cell death or (2) binding and inactiva-
tion of RAD001 by serum components.
 In our cell model, 50% growth inhibition was observed 
with 20 n M RAD001 in serum-depleted and with 35 n M 
RAD001 in serum-rich medium. Significantly, the peak 
blood concentrations (C max ) in humans after oral RAD001 
doses of 0.5 mg, 1.0 mg, 2.0 mg and 4.0 mg were approxi-
mately 5 n M , 12 n M , 23 n M and 46 n M  [31] . As in several 
clinical studies of mTOR-targeted cancer therapy RAD001 
is well tolerated when administered in oral dosages of 5–10 
mg/day  [32, 33] , RAD001 concentrations significantly in-
ducing antiproliferative effects in neuroendocrine cancer 
will probably be achievable with a good safety profile.
 It has been shown that rapamycin and its derivatives 
inhibit the binding of raptor to mTOR and thus block 
downstream phosphorylation of p70S6K and 4EBP1  [6] . 
Here, RAD001 treatment completely abrogated phos-
phorylation of p70S6K in BON cells. As p70S6K enhances 
the general translation capacity, its dephosphorylation 
might result in reduced cell size and motility. Several stud-
ies reported rapamycin and its derivatives to induce G0/
G1 phase arrest due to increased turnover and impaired 
translation of cyclin D1 mRNA  [34, 35] . Furthermore, ra-
pamycin has been shown to increase the expression of the 
cyclin-dependent kinase (cdk) 2 inhibitor p27Kip1 at 
mRNA and protein level  [36] . Consistently we found 
RAD001 to increase the number of BON cells in the G0/
G1 phase and this in fact was associated with decreased 
cyclin D1 and increased p27Kip1 protein levels. Whereas 
G0/G1 phase arrest due to mTOR inhibition by rapamycin 
and RAD001 has been reported for many tumor cell lines, 
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 Fig. 4. RAD001 induces apoptosis. BON cells were incubated with 
indicated concentrations of RAD001.  a After 24 h of incubation, 
the extent of caspase-3/PARP cleavage was examined using West-
ern blot analysis. One representative blot out of three performed 
experiments is shown.  b After 48 h of incubation, the proportion 
of cells with fragmented DNA was analyzed by flow cytometry. 
Values are demonstrated as average and SD of triplicate values 
from the same experiment and were confirmed by 3 independent 
separate experiments.  * * * p  ! 0.001 vs. untreated control. 
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only a relatively limited number of studies showed rapa-
mycin and its derivatives to induce apoptosis  [6, 37] . In 
BON cells, RAD001 dose-dependently induced apoptosis 
as demonstrated by caspase-3 cleavage, PARP cleavage 
and DNA fragmentation. One link between mTOR inhibi-
tion and apoptosis might again be provided by p70S6K, as 
dephosphorylation of p70S6K has been suggested to fa-
cilitate activation of the pro-apoptotic protein BAD  [6] .
 Recently, a study by O’Reilly et al. [3] demonstrated 
mTOR inhibition to result in an upregulation of PI(3)K/
Akt/mTOR signaling by relieving the negative p70S6K-
mediated feedback-inhibition on IRS-1. Consistently, we 
found that RAD001 increased Akt signaling in neuroen-
docrine BON tumor cells. As upregulation of Akt signal-
ing has been hypothesized to attenuate the antiprolifera-
tive efficacy of mTOR inhibitors, combinatorial therapy 
with PI(3)K inhibitors can be suggested to be a promising 
approach to enhance the antiproliferative effects of 
RAD001 in NETs and other malignancies. In support of 
this hypothesis, combined administration of rapamycin 
and the PI(3)K inhibitor LY294002 has recently been 
demonstrated to exhibit additive antiproliferative effects 
on non-small cell lung cancer cells  [28] . A phase II clini-
cal trial, evaluating the effects of combinatorial therapy 
with RAD001 and the somatostatin analogue octreotide 
showed promising results in patients with advanced low 
grade neuroendocrine carcinoma with partial remission 
in 15% and stable disease in 19 from 32 patients  [38] . As 
somatostatin also inhibits PI(3)K activity  [39] , these ef-
fects might be due to simultaneous inhibition of mTOR 
and an upstream inhibitory effect on PI(3) kinase. In 
summary, our present findings indicate the mTOR in-
hibitor RAD001 to be a promising agent for antiprolif-
erative NET treatment. Given the upregulation of Akt 
phosphorylation by RAD001, the effectiveness of com-
bined mTOR- and PI(3)K/Akt inhibition should be fur-
ther investigated.
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